Cancer / Immunology
Bambusa Therapeutics Closes $90 Million Series A to Advance Bispecific Antibody Pipeline for Immunological and Inflammatory Disorders
Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, anno...
February 17, 2025 | News
Alphamab Oncology Doses First Patient in Phase III Study of Anti-HER2 ADC JSKN003 for Platinum-Resistant Ovarian Cancer
Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...
February 14, 2025 | News
Lion TCR Secures FDA Clearance for Phase 2 Trial of Pioneering mRNA TCR-T Therapy for Liver Cancer
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug A...
February 12, 2025 | News
Pfizer and Astellas Announce Sustained Survival Benefit in Advanced Urothelial Cancer with PADCEV® and KEYTRUDA® Combination
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination a...
February 11, 2025 | News
Alphamab Oncology and CSPC Launch Phase III Trial for Anti-HER2 ADC JSKN003 in Advanced Breast Cancer
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has rece...
February 07, 2025 | News
Lunit Partners with SITC to Launch AI-Powered Research Program for Cancer Immunotherapy
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a partnership with the Society ...
February 04, 2025 | News
Kazia Therapeutics Launches Clinical Trial for Paxalisib-Immunotherapy Combination in Advanced Breast Cancer
Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial eval...
January 31, 2025 | News
Ryght AI and Cancer Research South Australia Partner to Accelerate Cancer Clinical Trials in Australia with AI
Ryght AI, a leading provider of real-time generative AI solutions for the clinical research industry, and Cancer Research South Australia (CRSA), a premier...
January 29, 2025 | News
Clarity Pharmaceuticals Secures Second FDA Fast Track Designation for 64Cu-SAR-bisPSMA in Prostate Cancer Imaging
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation product...
January 27, 2025 | News
GC Cell Hosts Landmark Symposium in Indonesia to Spotlight Immuncell-LC Cancer Immunotherapy
GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....
January 24, 2025 | News
GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy
GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...
January 23, 2025 | News
Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers
Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...
January 23, 2025 | News
AstraZeneca and Daiichi Sankyo’s DATROWAY Secures First US Approval for HR-Positive, HER2-Negative Breast Cancer
First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of d...
January 20, 2025 | News
IMPACT Therapeutics’ Senaparib Gains NMPA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthet...
January 17, 2025 | News
Most Read
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
